Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This review examines the current research on chemopreventive agents for prostate cancer, highlighting that while no definitive strategies have been confirmed, substances like finasteride, selenium, and vitamin E show promise in reducing risk.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

This case report links sorafenib treatment in a 22-year-old man with relapsed acute myeloid leukemia to a rare instance of drug-induced pityriasis rubra pilaris-like eruption.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study suggests that compounds from Sansevieria trifasciata Prain may have promising potential as effective 5α-reductase inhibitors for alopecia treatment, outperforming finasteride in binding affinity tests.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This case report identifies hand-foot and stump syndrome as a potential side effect of sorafenib therapy in a 47-year-old man with a leg amputation.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This study suggests that natural molecules like curcumin, EGCG, barringtozenol, and finasteride may be effective inhibitors for VEGFR, potentially offering a cancer chemoprevention alternative to pazopanib.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that fruit extracts from certain Egyptian Sabal species demonstrated significant anti-androgenic activity and potential therapeutic effects against benign prostatic hyperplasia in rat models and cell lines.

This case report observed that hypogonadism and cold sensation resolved in a patient after discontinuing 5-alpha-reductase inhibitors, suggesting these medications may contribute to such symptoms.

This study suggests that using opioids along with 5αRI may reduce opioid use disorder risk in humans, supporting similar findings from animal studies.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This study conducted molecular docking and ADME property analysis on 144 newly designed isatin analogs, suggesting they exhibit lead-like properties for targeting EGFR enzymes.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

In this study, the authors concluded that there is no clear difference in suicidal ideation between different 5α-reductase inhibitors, but results vary by finasteride dose, patient age, and psychiatric history.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study identified 29 Moroccan medicinal plants containing compounds that may act as natural inhibitors of SARS-CoV-2 based on molecular docking and in-silico analyses.

This review explores potential early-stage pharmacologic interventions for COVID-19 by targeting virus entry into host cells, identifying several existing drugs for further investigation, but reports no new clinical results.

This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.